ATE385777T1 - Nanopartikelzusammensetzungen von mitogen- aktivierten protein (map) kinase inhibitoren - Google Patents
Nanopartikelzusammensetzungen von mitogen- aktivierten protein (map) kinase inhibitorenInfo
- Publication number
- ATE385777T1 ATE385777T1 AT03723782T AT03723782T ATE385777T1 AT E385777 T1 ATE385777 T1 AT E385777T1 AT 03723782 T AT03723782 T AT 03723782T AT 03723782 T AT03723782 T AT 03723782T AT E385777 T1 ATE385777 T1 AT E385777T1
- Authority
- AT
- Austria
- Prior art keywords
- mitogen
- map
- kinase inhibitors
- activated protein
- nanoparticle compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36552402P | 2002-03-20 | 2002-03-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE385777T1 true ATE385777T1 (de) | 2008-03-15 |
Family
ID=28454669
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT03723782T ATE385777T1 (de) | 2002-03-20 | 2003-03-20 | Nanopartikelzusammensetzungen von mitogen- aktivierten protein (map) kinase inhibitoren |
Country Status (9)
Country | Link |
---|---|
US (1) | US20030181411A1 (de) |
EP (1) | EP1490025B1 (de) |
JP (2) | JP4611641B2 (de) |
AT (1) | ATE385777T1 (de) |
AU (1) | AU2003230692A1 (de) |
CA (1) | CA2479737C (de) |
DE (1) | DE60319073T2 (de) |
ES (1) | ES2302925T3 (de) |
WO (1) | WO2003080024A2 (de) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080102121A1 (en) * | 1998-11-02 | 2008-05-01 | Elan Pharma International Limited | Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone |
US20080113025A1 (en) * | 1998-11-02 | 2008-05-15 | Elan Pharma International Limited | Compositions comprising nanoparticulate naproxen and controlled release hydrocodone |
US20020119237A1 (en) * | 2000-12-22 | 2002-08-29 | Hevey Maurice O. | Medium and method for delivery of edible materials subject to degradation by oxidation and hydrolysis |
CA2475092C (en) | 2002-02-04 | 2012-05-01 | Christian F. Wertz | Nanoparticulate compositions having lysozyme as a surface stabilizer |
JP2006516548A (ja) | 2002-12-30 | 2006-07-06 | アンジオテック インターナショナル アクツィエン ゲゼルシャフト | 迅速ゲル化ポリマー組成物からの薬物送達法 |
US20080045706A1 (en) * | 2002-12-31 | 2008-02-21 | Flynn Daniel L | Anti-inflammatory medicaments |
US7202257B2 (en) * | 2003-12-24 | 2007-04-10 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
US7144911B2 (en) * | 2002-12-31 | 2006-12-05 | Deciphera Pharmaceuticals Llc | Anti-inflammatory medicaments |
US7279576B2 (en) * | 2002-12-31 | 2007-10-09 | Deciphera Pharmaceuticals, Llc | Anti-cancer medicaments |
US20040248982A1 (en) * | 2003-06-09 | 2004-12-09 | Dyer Gordon Wayne | Use of compounds for the inhibition of proteins and UV protection |
ES2318330T3 (es) * | 2003-08-08 | 2009-05-01 | Elan Pharma International Limited | Nuevas composiciones de metaxalona. |
ES2366646T3 (es) * | 2003-11-05 | 2011-10-24 | Elan Pharma International Limited | Composiciones en forma de nanopartículas que tienen un péptido como estabilizante superficial. |
US7109163B2 (en) * | 2004-01-30 | 2006-09-19 | Ethicon, Inc. | Hemostatic compositions and devices |
US20060025485A1 (en) * | 2004-07-01 | 2006-02-02 | Kyle Holen | Hydroxybenazamide compounds for treatment of cancer |
JP2007223903A (ja) * | 2004-07-09 | 2007-09-06 | Takeda Chem Ind Ltd | 新規な固体分散体およびその製造方法 |
BRPI0607537A2 (pt) | 2005-04-12 | 2009-09-15 | Elan Pharma Int Ltd | formulações de derivado de quinazolina nanoparticulado |
WO2006132752A1 (en) * | 2005-05-10 | 2006-12-14 | Elan Pharma International Limited | Nanoparticulate and controlled release compositions comprising vitamin k2 |
MX2007014163A (es) * | 2005-05-10 | 2008-01-24 | Elan Pharma Int Ltd | Formulaciones de nanoparticulas de clopidogrel. |
BRPI0613540A2 (pt) * | 2005-06-03 | 2011-01-18 | Elan Pharma Int Ltd | formulações de imatinib mesilato nanoparticuladas |
EP1901728A2 (de) * | 2005-06-03 | 2008-03-26 | Elan Pharma International Limited | Acetaminophen-nanopartikelformulierungen |
WO2006133045A1 (en) * | 2005-06-03 | 2006-12-14 | Elan Pharma International, Limited | Nanoparticulate benidipine compositions |
JP2009517485A (ja) | 2005-06-08 | 2009-04-30 | エラン・ファルマ・インターナショナル・リミテッド | セフジトレンを含むナノ粒子状および制御放出組成物 |
WO2006135689A2 (en) * | 2005-06-09 | 2006-12-21 | Elan Pharma International, Limited | Nanoparticulate ebastine formulations |
CA2611741A1 (en) * | 2005-06-13 | 2006-12-28 | Elan Pharma International, Limited | Nanoparticulate clopidogrel and aspirin combination formulations |
CA2612384A1 (en) * | 2005-06-15 | 2006-12-28 | Elan Pharma International, Limited | Nanoparticulate azelnidipine formulations |
WO2007008537A2 (en) * | 2005-07-07 | 2007-01-18 | Elan Pharma International, Limited | Nanoparticulate clarithromycin formulations |
JP2009507925A (ja) * | 2005-09-13 | 2009-02-26 | エラン ファーマ インターナショナル リミテッド | ナノ粒子タダラフィル製剤 |
JP2009508859A (ja) | 2005-09-15 | 2009-03-05 | エラン ファーマ インターナショナル リミテッド | ナノ粒子アリピプラゾール製剤 |
MX2008015275A (es) | 2006-05-30 | 2009-02-06 | Elan Pharma Int Ltd | Formulaciones de posaconazol en nanoparticulas. |
JP2009540010A (ja) * | 2006-06-13 | 2009-11-19 | エラン ファーマ インターナショナル,リミティド | ナノ粒子状のキナーゼインヒビター製剤 |
KR20090031618A (ko) * | 2006-07-12 | 2009-03-26 | 엘란 코포레이션, 피엘씨 | 나노입자형 모다피닐 제제 |
KR101434706B1 (ko) * | 2007-02-16 | 2014-08-26 | 아스카 세이야쿠 가부시키가이샤 | 미립자 유성 현탁액을 포함하는 의약 조성물 |
US20080279784A1 (en) * | 2007-05-07 | 2008-11-13 | Questcor Pharmaceuticals, Inc. | Nasal administration of benzodiazepines |
US8530463B2 (en) * | 2007-05-07 | 2013-09-10 | Hale Biopharma Ventures Llc | Multimodal particulate formulations |
WO2009117401A2 (en) * | 2008-03-21 | 2009-09-24 | Elan Pharama International Limited | Compositions for site-specific delivery of imatinib and methods of use |
CA2756690C (en) | 2008-03-28 | 2016-08-16 | Hale Biopharma Ventures, Llc | Administration of benzodiazepine compositions |
US8110608B2 (en) | 2008-06-05 | 2012-02-07 | Ecolab Usa Inc. | Solid form sodium lauryl sulfate (SLS) pesticide composition |
EP2172193A1 (de) | 2008-10-02 | 2010-04-07 | Capsulution Nanoscience AG | Verbesserte Nanopartikel-Zusammensetzungen schlecht löslicher Verbindungen |
AU2010254180B2 (en) | 2009-05-27 | 2015-08-27 | Alkermes Pharma Ireland Limited | Reduction of flake-like aggregation in nanoparticulate active agent compositions |
TR200904500A2 (tr) | 2009-06-10 | 2009-10-21 | Öner Levent | Ezetimib nanokristallerinin hazırlanması için yöntem ve farmasötik formülasyonları. |
EP2490679B8 (de) * | 2009-10-22 | 2022-10-26 | Tpc-Api Llc | Verfahren zur herstellung und verwendung von zusammensetzungen mit flavonoiden |
US8637569B2 (en) | 2009-10-22 | 2014-01-28 | Api Genesis, Llc | Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds |
US8968757B2 (en) | 2010-10-12 | 2015-03-03 | Ecolab Usa Inc. | Highly wettable, water dispersible, granules including two pesticides |
WO2012174158A2 (en) | 2011-06-14 | 2012-12-20 | Hale Biopharma Ventures, Llc | Administration of benzodiazepine |
KR101794032B1 (ko) * | 2011-09-21 | 2017-11-07 | (주)바이오시네틱스 | 나노입자 제조방법 |
EP3368040B1 (de) * | 2015-10-26 | 2022-08-17 | Eip Pharma, LLC | Verfahren und zusammensetzungen zur erholung nach einem schlaganfall |
WO2019056003A1 (en) | 2017-09-18 | 2019-03-21 | Eip Pharma, Llc | CO-CRYSTALS FROM NEFLAMAPIMOD (VX -745) |
JP2020152673A (ja) | 2019-03-20 | 2020-09-24 | 株式会社リコー | ナノ粒子及びナノ粒子の製造方法、並びに医薬 |
CA3144945A1 (en) * | 2019-06-26 | 2020-12-30 | Ricoh Company, Ltd. | Pharmaceutical composition including particles containing a water-soluble base material and a poorly water-soluble compound |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2608988B1 (fr) * | 1986-12-31 | 1991-01-11 | Centre Nat Rech Scient | Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules |
US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
US5834025A (en) * | 1995-09-29 | 1998-11-10 | Nanosystems L.L.C. | Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions |
JP4107693B2 (ja) * | 1996-02-09 | 2008-06-25 | 保土谷化学工業株式会社 | 固体粒子水性懸濁液の製造方法 |
US6361938B1 (en) * | 1996-11-08 | 2002-03-26 | Elan Corporation, Plc | Peptides which enhance transport across tissues and methods of identifying and using the same |
EP2168593A1 (de) * | 1998-09-01 | 2010-03-31 | Merrion Research III Limited | Orale impfstoff-zusammensetzung |
WO2000018374A1 (en) * | 1998-10-01 | 2000-04-06 | Elan Pharma International, Ltd. | Controlled release nanoparticulate compositions |
EP1261334A1 (de) * | 1998-10-20 | 2002-12-04 | Omeros Corporation | Spüllösung enthaltend mapk hemmern und deren verwendung zur behandlung von schmerz und entzündung |
US6375986B1 (en) * | 2000-09-21 | 2002-04-23 | Elan Pharma International Ltd. | Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate |
US6656504B1 (en) * | 1999-09-09 | 2003-12-02 | Elan Pharma International Ltd. | Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions |
CN1382044A (zh) * | 1999-09-17 | 2002-11-27 | 史密丝克莱恩比彻姆公司 | 细胞因子抑制性抗炎药在鼻病毒感染中的用途 |
-
2003
- 2003-03-20 JP JP2003577854A patent/JP4611641B2/ja not_active Expired - Fee Related
- 2003-03-20 AT AT03723782T patent/ATE385777T1/de not_active IP Right Cessation
- 2003-03-20 WO PCT/US2003/008547 patent/WO2003080024A2/en active IP Right Grant
- 2003-03-20 EP EP03723782A patent/EP1490025B1/de not_active Expired - Lifetime
- 2003-03-20 DE DE60319073T patent/DE60319073T2/de not_active Expired - Lifetime
- 2003-03-20 CA CA2479737A patent/CA2479737C/en not_active Expired - Fee Related
- 2003-03-20 ES ES03723782T patent/ES2302925T3/es not_active Expired - Lifetime
- 2003-03-20 AU AU2003230692A patent/AU2003230692A1/en not_active Abandoned
- 2003-03-20 US US10/392,303 patent/US20030181411A1/en not_active Abandoned
-
2010
- 2010-07-28 JP JP2010168818A patent/JP2010280685A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
DE60319073D1 (de) | 2008-03-27 |
CA2479737A1 (en) | 2003-10-02 |
DE60319073T2 (de) | 2009-02-05 |
JP4611641B2 (ja) | 2011-01-12 |
JP2010280685A (ja) | 2010-12-16 |
AU2003230692A1 (en) | 2003-10-08 |
AU2003230692A8 (en) | 2003-10-08 |
WO2003080024A3 (en) | 2004-04-08 |
EP1490025A2 (de) | 2004-12-29 |
EP1490025B1 (de) | 2008-02-13 |
JP2005526785A (ja) | 2005-09-08 |
WO2003080024A2 (en) | 2003-10-02 |
CA2479737C (en) | 2011-05-24 |
US20030181411A1 (en) | 2003-09-25 |
ES2302925T3 (es) | 2008-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE385777T1 (de) | Nanopartikelzusammensetzungen von mitogen- aktivierten protein (map) kinase inhibitoren | |
ATE343376T1 (de) | Nanopartikelzusammensetzungen von angiogeneseinhibitoren | |
CY1107810T1 (el) | Συνθεσεις οι οποιες εχουν ενα συνδυασμο χαρακτηριστικων αμεσης απελευθερωσης και ελεγχομενης απελευθερωσης | |
BRPI0519088A2 (pt) | formulaÇÕes de tacrolimo nanoparticuladas | |
MX2010009866A (es) | Composiciones de inhibidores de angiogenesis en nanoparticulas. | |
DE602004021107D1 (de) | Meloxican-formulierungen in nanoteilchenform | |
ATE457718T1 (de) | Sterile gefilterte nanoteilchen-formulierungen von budesonid mit tyloxapol als oberflächenstabilisator | |
ATE419835T1 (de) | Nystatin-nanopartikelzusammensetzungen | |
WO2005027962A3 (en) | 4’-thionucleosides and oligomeric compounds | |
AU2464601A (en) | Tricyclic protein kinase inhibitors | |
IS6950A (is) | Samsetning epóþílonhliðstæðna og efnameðferðarlyfja til meðhöndlunar frumufjölgunarsjúkdóma | |
EA200501017A1 (ru) | Астма и модуляторы аллергических воспалений | |
ATE248170T1 (de) | Kinase-inhibitoren mit hoher affinität zur ziel detektion und ihre verwendung | |
DE60138308D1 (de) | Herstellung von feinkörnigen teilchen | |
CY1106115T1 (el) | Προσδιορισμος κινασης αναπλαστικου λεμφωματος, αντιδραστηρια και συνθεσεις αυτης | |
WO2001075178A3 (en) | Methods for identifying peptide aptamers capable of altering a cell phenotype | |
WO2003040168A3 (en) | Methods and compositions for identifying peptide aptamers capable of altering a cell phenotype | |
DE602005025082D1 (de) | Nicht-lamellare zubereitungen von dioleoyl-phosphatidyl ethanolamin und polysorbat80 | |
WO2002068476A3 (en) | Composition comprising il-22 inhibitors and use thereof for treating inflammatory disorders | |
WO2002083622A3 (en) | Novel aminophenyl ketone derivatives | |
NO20006026L (no) | Fremgangsmåter og blandinger for modulering av angiogenese ved bruk av tyrosin kinase SRC | |
BR0208961A (pt) | Composição farmacêutica demonstrando atividade anti-tumor, método para fabricar a mesma, e uso de uma tolueno sulfonamida | |
WO2005023744A3 (en) | Calixarenes as inhibitors of protein kinase b | |
EP1938803A3 (de) | Formulierungen mit Nanoteilchen-Meloxican | |
ATE552342T1 (de) | An der bildung von knöllchen und endomykorrhiza beteiligte ccamk |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |